反応式
[CH3:1][C:2]([C:6]1[NH:10][CH:9]=[N:8][C:7]=1/[CH:11]=[C:12]1/[C:13]([NH:15][C@@H:16]([CH2:20][C:21]2[CH:26]=[CH:25][CH:24]=[CH:23][CH:22]=2)[C:17]([NH:19]/1)=[O:18])=[O:14])([CH:4]=[CH2:5])[CH3:3].N[C@H](C(O)=O)CC1C=CC=CC=1>CCCCCC.C(O)C>[CH3:3][C:2]([C:6]1[NH:10][CH:9]=[N:8][C:7]=1/[CH:11]=[C:12]1/[C:13]([NH:15][C@H:16]([CH2:20][C:21]2[CH:22]=[CH:23][CH:24]=[CH:25][CH:26]=2)[C:17]([NH:19]/1)=[O:18])=[O:14])([CH:4]=[CH2:5])[CH3:1]参加物
実験手順
It was also determined that phenylahistin has a chiral center at the C-10 position. Chiral HPLC analysis of the phenylalanine was conducted according to methods described in Larsen, T. O et al., Phytochemistry (1992) 31, 1613, under the following conditions: HPLC conditions: column; Crownpak CR(+) N4.0×150 mm (Daicel Chemical Industries, Ltd.), mobile phase; H2O (pH 2, adjusted with perchloric acid), flow rate; 0.8 ml/mn, detector; UV 8 200 nm. Phenylalanine was obtained from the acidic hydrolysate of the amorphous white powder of phenylahistin, see Yamazaki, M. et al., Tetrahedron Lett. (1975) 27. The phenylalanine obtained from the hydrolysate of phenylahistin was identified using an amino acid analyzer and by measurement of EI-MS [(m+H)+:166.2]); chrial HPLC indicated that the phenylahistin was a mixture of enantiomers in the ratio of approximately R:S=3.1. In order to examine the biological activity of each enantiomer, chiral resolution was carried out by chiral HPLC under the following conditions: column; Chiracel OD N4.6×250 mm (Daicel Chemical Industries, Ltd), mobile phase; n-hexane/ethanol=75/25, flow rate; 1.0 ml/min, temperature; 25° C. Absolute configuration was determined by analysis of phenylalanine obtained from (+)-phenylahistin using chiral HPLC.
後処理
- additiona mixture of enantiomers in the ratio of approximately R
- custom25° C
出典と根拠
- ORDレコード
- ord-a19ff513838e4c26b480bc7134194942
- 出典データセット
- uspto-grants-2004_03
- 特許番号
- US06713480B2
関連ノート
読み込み中…